VisCardia Announces Publication of RECOVER-HF Pilot Trial in JACC: Heart Failure
Publication marks a milestone for VisONE™ cardiac diaphragm support as enrollment continues in the RECOVER-HF pivotal IDE trialPORTLAND, Ore., Oct....
Clinical Trial
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in AustraliaHighlights Collaboration aims to accelerate precision...
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available...
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p 89% and...
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in...
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated...
One04 Therapeutics presents positive interim Phase 1 data for CPV-104 in C3 glomerulopathy in ASN Kidney Week late-breaker
Met predefined primary and secondary objectives for the interim analysis CPV-104 was generally well tolerated in healthy volunteers and patients...
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change...
Founded by MIT and Flagship Alum, AI Drug Discovery Company Reflector Bio Emerges from Stealth
The New York techbio company's biological foundation model predicts a compound’s efficacy in cells, adding a complementary signal to structure-based...
Beacon Biosignals Acquires Snap Diagnostics, Paving the Way for EEG-Enabled Home Sleep Testing in Every Care Setting
Acquisition more than doubles Beacon’s patient reach, creating a national channel to bring EEG-enabled home sleep testing to primary care,...
DEA’s Marijuana Rescheduling Defense Under Fire: The Fallout From GAO’s Procedural Findings
Duane Boise CEO of MMJ International Holdings: "The government restricted its own witness's testimony, then argued the other side already...
Alethios Unveils a Comprehensive Decentralized Data Collection Suite for Human Health Research
Live, no-code integrations let researchers combine participant-reported outcomes, wearables and sensors, AI-powered digital biomarkers, and at-home lab tests in a...
Levicept Announces Attendance at Major Healthcare Conferences in Q4
SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of...
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower...
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower...
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with...
Pharming Group announces third quarter 2026 revenues above market expectations
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total...
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth...
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for...